Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus acarbose monotherapy in drug-naive type 2 diabetes
ChiCTR-TRC-12002271Phase 4Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2010
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin and acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: HbA1c. Started Apr 2010; status: completed.
02
Drugs
sitagliptinacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-12002271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002271.